作者: Neil P Shah , Charles L Sawyers
关键词:
摘要: Philadelphia chromosome-associated leukemias are among the most well-understood human malignancies. The importance of BCR-ABL enzymatic activity in proliferation leukemic clone has been confirmed by high response rates these to ABL-selective tyrosine kinase inhibitor STI571, even advanced disease phases, which characterized increased genetic heterogeneity. Disease relapse observed a subset patients who had initially responded STI571. Evidence suggests that is restored majority cases acquired resistance. Molecular studies resistant leukemia cells isolated from have implicated domain point mutation as common mechanism Additionally, genomic amplification gene can occasionally be detected. This review will highlight mechanisms STI571 resistance clinical samples well preclinical models.